Selecta Biosciences Profit Margin

Selecta Biosciences (SELB) currently reports a profit margin of -10283.75% as of June 2026. That compares with -249.52% in the prior-year period — down 4021.5% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Selecta Biosciences's profit margin history and peer comparisons.

Selecta Biosciences's profit margin decreased from -249.52% to -10283.75% — a 4021.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Selecta Biosciences's profit margin of -10283.75% is lower than the Healthcare sector average of 13.89%. That is roughly 74120.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Selecta Biosciences's current -10283.75% should be judged against Healthcare norms (sector average: 13.89%) and against SELB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -10283.75%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Selecta Biosciences, and consider following SELB for alerts when major investors trade the stock.